Stacy Ann Coen - 02 Aug 2023 Form 4 Insider Report for ImmunoGen, Inc.

Role
SVP & CHIEF BUSINESS OFFICER
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
02 Aug 2023
Net transactions value
-$1,030,520
Form type
4
Filing time
04 Aug 2023, 19:33:10 UTC
Previous filing
05 Jul 2023
Next filing
11 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $20,935 +4,255 +39% $4.92 15,215 02 Aug 2023 Direct
transaction IMGN Common Stock Sale $77,101 -4,255 -28% $18.12 10,960 02 Aug 2023 Direct F1
transaction IMGN Common Stock Options Exercise $395,204 +80,326 +733% $4.92 91,286 04 Aug 2023 Direct
transaction IMGN Common Stock Sale $1,369,558 -80,326 -88% $17.05 10,960 04 Aug 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -4,255 -1.6% $0.000000 255,745 02 Aug 2023 Common Stock 4,255 $4.92 Direct F3
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -80,326 -31% $0.000000 175,419 04 Aug 2023 Common Stock 80,326 $4.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F3 Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.